124468 20241125101156.0 doi 10.1038/s41388-023-02604-x sideral 132909 ART-2023-132909 eng Scott, E. Upregulation of GALNT7 in prostate cancer modifies O-glycosylation and promotes tumour growth 2023 Access copy available to the general public Unrestricted Prostate cancer is the most common cancer in men and it is estimated that over 350,000 men worldwide die of prostate cancer every year. There remains an unmet clinical need to improve how clinically significant prostate cancer is diagnosed and develop new treatments for advanced disease. Aberrant glycosylation is a hallmark of cancer implicated in tumour growth, metastasis, and immune evasion. One of the key drivers of aberrant glycosylation is the dysregulated expression of glycosylation enzymes within the cancer cell. Here, we demonstrate using multiple independent clinical cohorts that the glycosyltransferase enzyme GALNT7 is upregulated in prostate cancer tissue. We show GALNT7 can identify men with prostate cancer, using urine and blood samples, with improved diagnostic accuracy than serum PSA alone. We also show that GALNT7 levels remain high in progression to castrate-resistant disease, and using in vitro and in vivo models, reveal that GALNT7 promotes prostate tumour growth. Mechanistically, GALNT7 can modify O-glycosylation in prostate cancer cells and correlates with cell cycle and immune signalling pathways. Our study provides a new biomarker to aid the diagnosis of clinically significant disease and cements GALNT7-mediated O-glycosylation as an important driver of prostate cancer progression. info:eu-repo/semantics/openAccess by http://creativecommons.org/licenses/by/3.0/es/ 6.9 2023 BIOCHEMISTRY & MOLECULAR BIOLOGY 36 / 313 = 0.115 2023 Q1 T1 ONCOLOGY 42 / 322 = 0.13 2023 Q1 T1 GENETICS & HEREDITY 16 / 191 = 0.084 2023 Q1 T1 CELL BIOLOGY 40 / 205 = 0.195 2023 Q1 T1 2.334 2023 Cancer Research 2023 Q1 Molecular Biology 2023 Q1 Genetics 2023 Q1 15.3 2023 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Hodgson, K. Calle, B. Turner, H. Cheung, K. Bermúdez, A. García Marqués, F. J. Pye, H. Yo, E. C. Islam, K. Oo, H. Z. McClurg, U. L. Wilson, L. Thomas, H. Frame, F. M. Orozco-Moreno, M. Bastian, K. Arredondo, H. M. Roustan, C. Gray, M. A. Kelly, L. Tolson, A. Mellor, E. Hysenaj, G. Goode, E. A. Garnham, R. Duxfield, A. Heavey, S. Stopka-Farooqui, U. Haider, A. Freeman, A. Singh, S. Johnston, E. W. Punwani, S. Knight, B. McCullagh, P. McGrath, J. Crundwell, M. Harries, L. Bogdan, D. Westaby, D. Fowler, G. Flohr, P. Yuan, W. Sharp, A. Bono, J. de Maitland, N. J. Wisnovsky, S. Bertozzi, C. R. Heer, R. Hurtado Guerrero, R. (orcid)0000-0002-3122-9401 Daugaard, M. Leivo, J. Whitaker, H Pitteri, S. Wang, N. Elliott, D. J. Schumann, B. Munkley, J. 42 (2023), 926–937 Oncogene ONCOGENE 0950-9232 9819044 http://zaguan.unizar.es/record/124468/files/texto_completo.pdf Versión publicada 3011989 http://zaguan.unizar.es/record/124468/files/texto_completo.jpg?subformat=icon icon Versión publicada oai:zaguan.unizar.es:124468 articulos driver 2024-11-22-12:09:22 ARTICLE